In Malaysia, prostate cancer has been the third-most common type of cancer among men since 2012, doctors caution.

Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

The TCR report forecasts that by 2032 prostate cancer will increase steadily and remain the number one cancer of concern ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

Bengaluru: Prostate cancer remains one of the most frequently diagnosed malignancies among men worldwide, including in India.

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic castration-resistant prostate cancer (mCRPC), whereas prostate-specific membrane ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC), but only as a combination therapy.

The tissue damage and anatomical distortion caused by primary prostate cancer treatment are major challenges for surgeons performing salvage surgery.

Men with non-metastatic forms are likely to live 'for many years' after diagnosis when active surveillance and other NCCN ...

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.